Concurrent Chemoradiotherapy Combined With Adjuvant Chemotherapy Treated Advanced Cervical Cancer

Launched by FOURTH AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY · Feb 16, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a treatment approach for women with locally advanced cervical cancer. Researchers want to find out if combining chemotherapy (medicine that kills cancer cells) with radiation therapy (high-energy rays that target cancer) followed by more chemotherapy is more effective than using radiation and chemotherapy alone. The goal is to improve treatment outcomes for patients and better understand the role of the additional chemotherapy after the initial treatment.

To participate in this trial, women aged 18 to 75 who have been diagnosed with certain types of cervical cancer (like squamous cell carcinoma or adenocarcinoma) and are in specific stages of the disease (stages IB3 to IVA) may be eligible. Participants should be in relatively good health, meaning they can carry out daily activities without much trouble, and they should not have other serious health conditions that could affect treatment. If eligible, participants can expect to receive close monitoring and care throughout the study, contributing to important research that may help improve future cancer treatments.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Cervical cancer confirmed by histopathology incloud squamous cell carcinoma, adenocarcinoma and adenosquamous carcinoma
• • FIGO stage IB3, IIA2, IIB-IVA patients in 2018
• • Locally advanced cervical cancer patients received standard concurrent intensity-modulated chemoradiotherapy followed by three-dimensional afterloading treatment after diagnosis, and the effect reached CR after treatment
• • Aged 18-75 years
• • PS score 0-1
• • Serum hemoglobin \>=100\*10\^9/L, blood platelet \>= 100000/μL, absolute count of neutrophils\>=1500/μL; 7.Serum creatinine \<=1.5 UNL or creatinine clearance \>= 60 ml/min; 8.Serum bilirubin \<=1.5 UNL, AST (SGOT) and ALT (SGPT)\<= 1.5 UNL
• • Sign a formal informed consent to show that they understand that the study is in line with hospital and national policies .Estimated total survival \> 6 months.
• Exclusion Criteria:
• • Locally advanced cervical cancer patients received standard concurrent intensity-modulated chemoradiotherapy followed by three-dimensional afterloading treatment after diagnosis, and the effect unreached CR after treatment
• • Patients who have received neoadjuvant chemotherapy and surgery
• • Patients with cognitive impairment
• • Patients with any distant metastases
• • Patients with any other malignancy within 5 years
• • Any other disease or condition is contraindications to chemoradiotherapy (e.g., active infection, 6 months after myocardial infarction, symptomatic heart disease, including unstable angina, congestive heart failure or uncontrolled arrhythmias, immunosuppressive therapy, etc.); 5.Pregnant or lactating women, or fertile women who do not use contraception
• • Severe bone marrow dysfunction
• • Patients with bleeding tendency
• • Drug abusers or alcohol addicts
• • Those who are known to have a third or fourth degree allergic reaction to any treatment in the study